INTERLEUKIN-15 + thymosin alpha 1

1 paper4 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab

Animals1

Outcomes

PI3K–AKT signalling

downin mice1

1 study

INTERLEUKIN-15 + thymosin alpha 1 inhibits PI3K–AKT signalling in mice.
“combination attenuated chronically overactivated phosphatidylinositol 3-kinase/protein kinase B signaling in hepatic CD8+ T cells.”
Animalsorthotopic HCC modelcombination therapyhepatic CD8+ T cells
IL-15 Plus Thymosin α1 Reduces Senescent Hepatic CD8⁺ T Cells in Hepatocellular Carcinoma via PI3K/AKT Suppression
Journal of gastroenterology and hepatology26 Mar 2026

Latest

1 in 12 months

Journal of Gastroenterology and Hepatology26 Mar

IL-15 Plus Thymosin α1 Reduces Senescent Hepatic CD8⁺ T Cells in Hepatocellular Carcinoma via PI3K/AKT Suppression

Experiments in miceHepatocellular carcinoma

Paper

INTERLEUKIN-15 + thymosin alpha 1

Outcomes

Latest

IL-15 Plus Thymosin α1 Reduces Senescent Hepatic CD8⁺ T Cells in Hepatocellular Carcinoma via PI3K/AKT Suppression

Related